The content on this site is intended for healthcare professionals only
Dr Fabregas explains how ASCO 2025 showcased the major advancements in gastrointestinal cancer treatments.
The MATTERHORN trial demonstrates that adding durvalumab immunotherapy to standard care for gastric cancer enhances event-free survival and pathologic response rates.
The ATOMIC trial reports a 50% increase in disease-free survival for colorectal cancer patients treated with atezolizumab and chemotherapy.
The BREAKWATER trial indicates improved overall survival for patients with BRAF-mutated colorectal cancer (CRC), with future research focusing on immunotherapy to reduce treatment-related toxicities.
ASCO 2025: Developments in the treatment of soft tissue sarcoma
Florida Atlantic University and Memorial Cancer Institute collaboration
Clinical advances in cancer molecular testing: the patient's perspective
Updates on gastrointestinal cancer treatments ASCO 2025
Understanding genetic aberrations in lung cancer treatment: NTRK, RET, NRG
Latest advances in chronic lymphocytic leukaemia
Future of chemotherapy and targeted therapies
Breast cancer survivorship
Burden and trends of breast cancer worldwide: Opportunities for prevention?
